Introduction: Alemtuzumab (C-1H) has been used off label in solid organ transplantation as an induction agent. It promotes long lasting lymphocyte depletion allowing for reduced maintenance immunosuppression without using long term steroids. Since 2004, Campath has been the induction agent of choice in our steroid free maintenance protocol in nearly 1000 renal allograft transplants in a population that is 70% African American.
Methods: Renal allograft recipients who received transplants between January 1, 2001 to December 31, 2011, were followed for overall patient and graft survival until April, 2012, stratified by induction method, Campath vs. Non Campath.
Results: 1080 patients were transplanted between January 1, 2001 and December 31, 2011. 632 patients received Alemtuzumab for Induction, and 448 patients received agents other than Campath. Please see table 1 for overall patient characteristics and survival outcomes.
Conclusion: Alemtuzumab induction allows steroid free maintenance in a single transplant center where 70% of the transplant population is African American. When compared to the non campath group, the outcomes were better despite the patients being higher risk.
To cite this abstract in AMA style:Light J, Tucker M, Orquiza M, Africa J. Alemtuzumab Induction and Steroid Free Maintenance in Predominately African American Renal Allograft Recipients [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/alemtuzumab-induction-and-steroid-free-maintenance-in-predominately-african-american-renal-allograft-recipients/. Accessed October 27, 2020.
« Back to 2013 American Transplant Congress